These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25834026)

  • 41. Cancer drug offers effective, cheaper option for AMD.
    Stephenson J
    JAMA; 2011 May; 305(20):2053-4. PubMed ID: 21610231
    [No Abstract]   [Full Text] [Related]  

  • 42. Experience of New Brunswick ophthalmologists using intravitreal anti-vascular endothelial growth factor.
    Giberson M; Taylor V
    Can J Ophthalmol; 2015 Oct; 50(5):393-4. PubMed ID: 26455977
    [No Abstract]   [Full Text] [Related]  

  • 43. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
    Chen G; Li W; Tzekov R; Jiang F; Mao S; Tong Y
    Retina; 2015 Feb; 35(2):187-93. PubMed ID: 25105318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52).
    Avery RL
    Ophthalmology; 2016 Feb; 123(2):e14-e16. PubMed ID: 26802717
    [No Abstract]   [Full Text] [Related]  

  • 45. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Shifting exudative age-related macular degeneration patients to ranibizumab after insufficient response to bevacizumab.
    de Geus SJ; Jager MJ; Luyten GP; Dijkman G
    Acta Ophthalmol; 2013 Aug; 91(5):e411-3. PubMed ID: 23551594
    [No Abstract]   [Full Text] [Related]  

  • 47. Age-related macular degeneration, anti-VEGF therapy, and ophthalmic imaging: is there a best practice?
    Han DP
    JAMA Ophthalmol; 2013 Sep; 131(9):1124-6. PubMed ID: 23744293
    [No Abstract]   [Full Text] [Related]  

  • 48. By the way, doctor. My 78-year-old husband has wet macular degeneration. He is being treated with a drug called Avastin. Is that a good choice?
    Heier JS
    Harv Health Lett; 2010 May; 35(7):6. PubMed ID: 20583361
    [No Abstract]   [Full Text] [Related]  

  • 49. [Initial experience with aflibercept in the management of patients with wet age-related macular degeneration refractory to ranibizumab and/or bevacizumab].
    Cervera RE; Castro V; Montero J; Torralba C; Gracia A
    Arch Soc Esp Oftalmol; 2014 Jan; 89(1):42-3. PubMed ID: 24269436
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.
    Kent JS; Iordanous Y; Mao A; Powell AM; Kent SS; Sheidow TG
    Can J Ophthalmol; 2012 Apr; 47(2):159-64. PubMed ID: 22560422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A new drug for macular degeneration. A breakthrough accomplished (interview by Waldtraud Paukstadt)].
    Holz FG
    MMW Fortschr Med; 2007 Jan; 149(3):13-4. PubMed ID: 17619376
    [No Abstract]   [Full Text] [Related]  

  • 52. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
    Berg K; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice.
    Studnička J; Říhová B; Rencová E; Rozsíval P; Dubská Z; Chrapek O; Kolář P; Kandrnal V; Demlová R; Pitrová Š; Řehák J
    Ophthalmologica; 2013; 230(1):34-42. PubMed ID: 23751929
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Switch from intravitreal ranibizumab to bevacizumab for the treatment of neovascular age-related macular degeneration: clinical comparison.
    Pinheiro-Costa J; Freitas-da-Costa P; Falcão MS; Brandão EM; Falcão-Reis F; Carneiro AM
    Ophthalmologica; 2014; 232(3):149-55. PubMed ID: 25196907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nice or not so nice.
    McColgan K
    J Perioper Pract; 2010 Nov; 20(11):386. PubMed ID: 21162353
    [No Abstract]   [Full Text] [Related]  

  • 58. One-year results of treatment with bevacizumab alone or ranibizumab alone for low visual acuity due to neovascular age-related macular degeneration.
    Ozkaya A; Alkin Z; Agca A; Satici T; Karakucuk Y; Yazici AT; Demirok A
    J Ocul Pharmacol Ther; 2013 Dec; 29(10):865-9. PubMed ID: 24053539
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of wet age-related macular degeneration by ranibizumab in "real life" in France: treatment behaviours and associated visual outcome.
    Souied EH; Cohen SY; de Pouvourville G; Dupeyron G; Latour E; Ponthieux A; Weber M
    Acta Ophthalmol; 2015 Mar; 93(2):e179-80. PubMed ID: 25377519
    [No Abstract]   [Full Text] [Related]  

  • 60. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.